60 degrees pharma announces irb approval of phase iia study to evaluate tafenoquine for babesiosis, an emerging tick-borne disease; type c meeting re-scheduled by fda to january 17, 2024

60 degrees pharma has received irb approval for a phase iia study evaluating tafenoquine's efficacy in treating hospitalized babesiosis patients, while the

SXTP Ratings Summary

SXTP Quant Ranking